View on Pubmed.gov 30006637 | View on doi.org 10.1038/s41598-...
Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance.
- University of Florida, College of Medicine, Emerging Pathogens Institute, Department of Molecular Genetics and Microbiology, Gainesville, FL, 32610, USA.
- University of Florida, College of Veterinary Medicine, Emerging Pathogens Institute, Department of Infectious Diseases and Immunity, Gainesville, FL, 32610, USA.
- University of Florida, College of Medicine, Emerging Pathogens Institute, Department of Molecular Genetics and Microbiology, Gainesville, FL, 32610, USA. Chulalongkorn University, Faculty of Veterinary Science, Department of Veterinary Public Health, Research Unit in Microbial Food Safety and Antimicrobial Resistance, Bangkok, 10330, Thailand.
- Cornell University, Boyd Thompson Institute, Ithaca, NY, 14853, USA.
- Colorado State University, College of Veterinary Medicine and Biomedical Sciences, Department of Microbiology, Immunology and Pathology, Fort Collins, CO, 80523, USA.
- The Medicines Company, San Diego, CA, 92121, USA.
- University of Florida, College of Medicine, Emerging Pathogens Institute, Department of Molecular Genetics and Microbiology, Gainesville, FL, 32610, USA. hschweizer@ufl.edu.
Abstract
Therapy of Burkholderia pseudomallei acute infections is largely limited to a few β-lactam antibiotics such as ceftazidime or meropenem. Although relatively rare, resistance emergence during therapy leads to treatment failures with high mortality rates. In the absence of acquired external resistance determinants in B. pseudomallei emergence of β-lactam resistance is invariably caused by mutational modification of genomically encoded factors. These include the deletion of the ceftazidime target penicillin-binding protein 3 or amino acid changes in the Class A PenA β-lactamase that expand its substrate spectrum, as well as penA gene duplication and amplification or its overexpression via transcriptional up-regulation. Evidence is presented that penA is co-transcribed with the upstream nlpD1 gene, that the transcriptional terminator for nlpD1 serves as a penA attenuator and that generation of a new promoter immediately upstream of the terminator/attenuator by a conserved G to A transition leads to anti-termination and thus constitutive PenA expression and extended β-lactam resistance. Further evidence obtained with the extensively β-lactam resistant clinical isolate Bp1651 shows that in addition to PenA overexpression and structural mutations other adaptive mechanisms contribute to intrinsic and acquired B. pseudomallei β-lactam resistance.
References
mBio. 2013 Nov 05;4(6):e00604-13
PLoS One. 2012;7(5):e37585
Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6557-6562
Emerg Infect Dis. 2012 Dec;18(12):e2
Cited by 20 citations (total)
Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.
Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei.
Electronic publication date June 19, 2023
Carina M Hall [...] Herbert P Schweizer et al.
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei...
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.
Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria.
Electronic publication date February 12, 2021
Nawarat Somprasong [...] Herbert P Schweizer et al.
, the founding member of the complex (Bpc), is a biothreat agent and causes melioidosis, a disease whose treatment...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •